Indications

ProBio SAP-90 probiotics is indicated to effectively reduce risk of diarrhea, enhance the immune system, prevent infections and maintain a good balance of intestinal micro-organisms (colon health).

Ingredients

Each dairy-free enteric-coated vegetable capsule contains:
Total active live probiotic cells 11 billion
L. rhamnosus B 4.4 billion
L. rhamnosus A 3.905 billion
L. acidophilus 550 million
L. plantarum 440 million
L. casei 440 million
B. longum 330 million
B. infantis 330 million
B. breve 330 million
S. thermophilus 220 million
L. bulgaricus 55 million
Plus Fructo-oligosaccharides (FOS) Inulin 10 mg
Arabino-oligosaccharides (AOS) 10 mg
Made from: 10 specific strains of live cells, chicory root and Larch Tree (Fiber).
In a non-GMO, water-based, vegetable capsule.

Description

ProBio SAP-90 is a high dose, multi-strain probiotic blend in an enteric coating which allows for nearly 100% delivery of live probiotic bacteria to the lower intestine.
Research supports that probiotics contribute to health through:
1. Competitively excluding enteric pathogens (via adhesion sites and nutrients);
2. Inhibiting growth of potential pathogens by producing lactic acid, bacteriocins, etc.;
3. Triggering cytokine synthesis from enterocytes by attaching to their surface;
4. Restoring the normal intestinal flora and improving microbial balance;
5. Producing toxic metabolites (e.g. hydrogen peroxide);
6. Modulating the immune system; and
7. Producing butyric acid (increased turnover of enterocytes, neutralization of dietary carcinogens).
Enhancement of the Immune System
Probiotics have been shown to influence some aspects of host immune function by involving one or several components of an immune response, e.g., humoral, cellular or nonspecific immunity. Although specific results have varied, generally probiotics enhance IgA production and antibody response, and nonspecifically influence immune responses by enhancing phagocytosis of pathogens as well as modifying cytokine production, such as tumor necrosis factor α and interleukin 6(8,9).
Promotion of Gut Health
In addition to immune function, there are many ways that probiotics may act to promote gut health. Infectious diarrheas and GI disorders, such as irritable bowel syndrome, are conditions that lack microbial balance favouring the development of harmful species. Probiotics return microbial balance through competition with pathogenic microorganisms for nutrients and binding sites on epithelial cells. As well, by producing bacteriocins (antimicrobial substances), organic acids and hydrogen peroxide, probiotics inhibit the growth of pathogenic bacteria(1,7,9,10). Probiotics may also aid in the recovery of intestinal permeability, aid in providing nutrition to the colonocytes by forming short chain fatty acids and some amino acids, stimulating proliferation of colonocytes and participating in the regulation of intestinal functions(11). Evidence also supports a reduction in the duration and symptoms of acute diarrhea, traveler's diarrhea and antibiotic-associated diarrhea(9). Furthermore, irritable bowel disease (IBD) is characterized by chronic and reoccurring intestinal infections, ulcerative cholitis, Crohn's disease and pouchitis. Although few, some human trials show that probiotics may play a role in the maintenance of remission in IBD patients(1).
Alleviation of Lactose Intolerance Symptoms
Worldwide, 70% of the population suffers from lactose maldigestion. Studies have shown that probiotics effectively improve lactose digestion in lactose malabsorbers. These beneficial effects are due to microbial beta-galactosidase that supports lactose digestion, delayed gastric emptying and slowed intestinal transit, which decreases the osmotic load of the lactose(12). Prevention of Carcinogenesis and Tumor Growth Anticancer activity is probably one of the most controversial health-related effects attributed to probiotics. The mechanisms of action by which probiotics may effectively reduce cancer risk, specifically colorectal cancer, include binding to mutagenic compounds in the intestine, thereby decreasing the absorption of these mutagens, and suppressing activity of enzymes that convert procarcinogens into carcinogens, consequently reducing intestinal carcinogen levels(10).
Reduction of Serum Lipids
Some human studies suggest a moderate cholesterol-lowering action of probiotics. Probiotics produce short-chain fatty acids in the gut, which can lead to a decrease in circulating blood lipids by inhibiting hepatic cholesterol synthesis and/or redistributing cholesterol from plasma to the liver. Furthermore, some bacteria may interfere with cholesterol absorption from the gut by deconjugating bile salts affecting the metabolism of cholesterol, or by directly assimilating cholesterol, promoting the excretion of dietary cholesterol in the feces(10,13).

Quantity

90 capsules

Dose

ADULT DOSAGE
1-3 capsules daily with a glass of water or juice, or as directed by your physician.

Potential side effects/Safety

The safety record of probiotics is excellent, with lactobacilli and bifidobacteria being generally recognized as safe (GRAS)1. The lack of pathogenicity with probiotic use extends to all age groups and to immunocompromised individuals(4). While, theoretically, as living organisms, probiotics may be responsible for side effects in susceptible individuals including infections, deleterious metabolic activities, excessive immune stimulation and gene transfer(5), lactobacilli and bifidobacteria probiotics are extremely rare causes of infections in humans and have not lead to an increase in such opportunistic infections in consumers. On these bases, probiotics are considered safe for human consumption.

References

"Show references"

"Hide references"

1. Saarela M, Lahteenmaki L, et al. Int J Food Microb 2002;78:99-117.
2. Gibson GR, Roberfroid MB. J Nutr 1995;125:1401-1412.
3. Robinson RR, Feirtag J, Slavin JL. J Am Coll Nutr 2001;20:279-285.
4. Schrezenmeir J, de Vrese M. Am J Clin Nutr 2001;73:361-364S.
5. Borriello SP, Hammes WP, Holzapfel W, et al. CID 2003;36:775-780.
6. Marteau P. Best Prac Res Clin Gastroenterol 2003;17:725-740.
7. Kaur IP, Chopra K, Saini A. Eur J Pharma Sci 2002;15:1-9.
8. Isolauri E, Sutas Y, Kankaanpaa P, et al. Am J Clin Nutr 2001;73:444S-450S.
9. Mombelli B, Gismondo MR. Int J Antimicr Agent 2000;16:531-536.
10. de Roos NM, Katan MB. Am J Clin Nutr 2000;71:405-11.
11. Fric P. Z Gastroenterol 2002;40:197-201.
12. Roberfroid MB. Am J Clin Nutr 2000;71:1682S-1687S.
13. Pereira DIA, Gibson GR. Crit Rev Biochem Mol Biol 2002;37:259-281.